What the FDA labels say about taking them together
Rasagiline and selegiline
Rasagiline's FDA label of June 30, 2020 names selegiline in its warnings and precautions section, and selegiline's label names rasagiline too. The selegiline label: “… non-selective MAOI or selective MAO-B inhibitors, such as selegiline (ELDEPRYL), rasagiline (AZILECT), and olanzapine (Zydis) selegiline (ZELAPAR).”
Check it at the source: the rasagiline FDA label on DailyMed (effective June 30, 2020, Teva Pharmaceuticals USA, Inc.); the selegiline FDA label on DailyMed (effective August 7, 2024, Rising Pharma Holdings, Inc.).
What does the rasagiline label say about selegiline?
Rasagiline label, warnings and precautionsSerotonin syndrome has been reported with concomitant use of an antidepressant (e.g., selective serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a nonselective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (Eldepryl) and rasagiline.
Source: FDA drug label (Rasagiline), Teva Pharmaceuticals USA, Inc., effective June 30, 2020 (SPL set e802c83c-e581-4a11-b83d-1df47120078d), via openFDA; the full label on DailyMed
What does the selegiline label say about rasagiline?
Zelapar label (Bausch Health US, LLC, June 1, 2021), warnings and precautionsSerotonin syndrome and hyperpyrexia have been reported with the combined treatment of an antidepressant (e.g., selective serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a non-selective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (ELDEPRYL), rasagiline (AZILECT), and olanzapine (Zydis) selegiline (ZELAPAR).
Source: FDA drug label (Zelapar, NDA021479), Bausch Health US, LLC, effective June 1, 2021 (SPL set 380d7717-2a79-42f3-a712-efe5e7696ba0), via openFDA
Source: FDA drug label (Selegiline Hydrochloride), Rising Pharma Holdings, Inc., effective August 7, 2024 (SPL set 23c4481f-d150-40c6-addb-b3e454ca914f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rasagiline | Selegiline | |
|---|---|---|
| Labeled for | Parkinson's disease | Parkinson's disease, Depression |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.521 per tablet 0.5 mg tablet | $0.756 per capsule 5 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once